【レポートの概要(一部)】
1. Report Overview
1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Overview of the AMD and Other Retinal Diseases Market, 2014-2025
2.1 Market to Make Rapid Strides to 2025
2.2 Lucentis Still Holds Over 60% of the Total Market
2.2.1 Novartis the Leading Presence in the Market
2.3 Which are the Most Significant Disease Areas for the Market?
2.3.1 Nearly 200 Million People with AMD?
2.3.2 Over 100 Million with DR
2.3.3 First RVO Estimates Suggest Patient Population of 16 Million
2.3.4 Wet AMD Still the Main Source of Revenues in the Market
2.4 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
2.5 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
2.6 DR: Coming Into Clinical Focus, with DME the Main Target
2.7 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
2.8 Projections for All Segments, 2014-2025
3. Approved Products in the AMD and Other Retinal Diseases Market, 2014-2025
3.1 Will the Current Products Dominate the Market Through 2025?
3.2 Lucentis: The Market Leader, But For How Long?
3.2.1 Shadow of Avastin Still Hangs Over Lucentis
3.2.2 CATT Study Results: Clinical Differences Still Have Yet to Emerge
3.2.3 Eylea: The Bigger Threat to Lucentis?
3.2.4 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
3.2.5 Improving Cost and Compliance for Lucentis
3.2.6 Will Loss of Physician Goodwill Harm Lucentis’ Growth?
3.2.7 Lucentis Revenue Forecast 2014-2025
3.3 Eylea: Pretender to the Throne?
3.3.1 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
3.3.2 First Wave of Eylea’s Expansion Finally Beginning to Break?
3.3.3 Into DME and Other New Indications
3.3.4 Zaltrap Targeting Solid Tumour Markets
3.3.5 How Far Can Eylea’s Momentum Carry It?
3.3.6 Eylea Revenue Forecast 2014-2025
3.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
3.4.1 Judicial Review Averted in the UK by Price Adjustment
3.4.2 Multiple Attempts to Block Off-Label Avastin Since 2007
3.4.3 Roche and Novartis Challenge CATT’s Headline Conclusions
3.4.4 Will Eylea/Zaltrap Affect Avastin’s Place in the Market?
3.4.5 Will Anything Dislodge Avastin from its Central Position?
3.4.6 Avastin Revenue Forecast, 2014-2025
3.5 Visudyne (Valeant/Novartis): Declining Sales Throughout the Forecast Period
3.5.1 Visudyne Revenue Forecast, 2014-2025
3.6 Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013
3.6.1 Jetrea Revenue Forecast, 2014-2025
4. Wet AMD Segment, 2014-2025
4.1 Eylea: The Segment’s Biggest Short-Term Driver
4.2 Pipeline for wAMD: The Leading Candidates
4.3 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
4.3.1 Three Phase 3 Trials to Confirm Fovista’s Outstanding Phase 2 Results
4.3.2 Ophthotech Goes Public to Fund Phase 3 Effort
4.3.3 Ophthotech Partners with Novartis for Fovista
4.3.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
4.3.5 The Move toward Combination Therapies
4.4 Other Growth Factor Targets in the Pipeline
4.4.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
4.4.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
4.4.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
4.4.4 iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
4.5 Conbercept (Chengdu Kanghong Biotech): The Other Phase 3 Candidate in wAMD
4.5.1 A Chinese Competitor: Where Will Conbercept Fit In?
4.5.2 Binding Affinity Comparable to Eylea
4.6 Do We Need New Anti-VEGFR Agents or Delivery Systems?
4.6.1 AGN-150998 DARPin (Allergan): Novel Protein With Extended Half-Life
4.6.2 ESBA 1008 (Alcon): Single-Chain Monoclonal Antibody Fragment
4.6.3 PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
4.6.4 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
4.6.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
4.6.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
4.7 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
4.7.1 Verisome System and IBI-30089 (Icon Bioscience)
4.7.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
4.8 Other Targets Under Investigation in wAMD Drug Development
4.8.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
4.8.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
4.8.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
4.8.4 First Ophthalmic Complement Factor Inhibitor, AL-78898A (Alcon), Misses Primary Endpoint
4.8.5 Factor C5: A More Promising Target Addressed by ARC1905 Aptamer (Ophthotech) and LFG316 (Novartis)
4.8.6 Integrins: Another Blockable Component of the Neovascularisation Cascade?
4.8.7 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
4.8.8 Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
4.8.9 Novel Anti-Angiogenic Treatments in Development: Ora Bio’s ORA102 and CoMentis’ ATG003
4.8.10 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
4.8.11 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
4.9 Regenerative Medicine Approaches
4.9.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
4.9.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
4.9.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes
5. Dry AMD Segment, 2014-2025
5.1 Dry AMD Segment to Emerge in the Forecast Period
5.2 Who Will Achieve the Big Breakthrough in Dry AMD?
5.3 MC-1101 (MacuCLEAR): Leading the Pack?
5.3.1 Increasing Choroidal Blood Flow with Repurposed Product
5.3.2 Novel Endpoints in Phase 3 Study
5.3.3 Can MacuCLEAR Make It?
5.4 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
5.4.1 Data Expected in July 2016
5.4.2 Other Visual Cycle Modulators
5.5 High Hopes for Complement Inhibition in Dry AMD
5.5.1 Lampalizumab (Roche): The Big News of ARVO 2013
5.5.1.1 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
5.5.2 AL-78898A (Alcon): Phase 2 Trial in Dry AMD Terminated
5.5.3 Soliris (Alexion): Out of the Running?
5.6 Corticosteroids: Targeting Inflammation’s Role in Dry AMD Pathogenesis
5.6.1 Medidur Fluocinolone Acetonide (Alimera Sciences): Insert in Phase 2
5.6.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
5.7 Neuroprotection: One of Modern Medicine’s Holy Grails
5.7.1 Tandospirone (Alcon): No News on Serotonin 1A Agonist
5.7.2 NT-501 (Neurotech): Some Promising Data in Dry AMD Studies
5.7.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
5.7.4 RN6G (Pfizer): Amyloid Beta-Binding Monoclonal Antibody Still in Studies
5.7.5 VAR10200 (Varinel): A Preclinical Candidate to Watch
5.8 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
5.8.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
5.8.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
5.8.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
5.8.4 Biotime: Stem Cell leader with Dry AMD Interests
5.8.5 First iPSC Trial in Japan in Dry AMD Patients
5.8.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
5.9 Other Treatments for Dry AMD
6. Diabetic Retinopathy Segment, 2014-2025
6.1 Segment to Grow in Importance as Diabetes Epidemic Continues
6.2 DR Options Grow with DME Addressed by New Agents
6.3 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
6.4 Lucentis: The Game Changer for DR?
6.5 New Anti-VEGF Additions
6.5.1 Is Eylea Better than Lucentis and Avastin for DME?
6.6 Steroids in Development for DR
6.6.1 Iluvien (Alimera/pSivida): New Option in European Markets
6.6.2 A New Hope? Optina (Ampio Pharmaceuticals)
6.6.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
6.6.4 SK-0503 (Sanwa Kagaku Kenkyusho): Potential DME and BRVO Treatment
6.6.5 Cortiject (Santen): Prodrug Candidate
6.6.6 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
6.7 Other Products in Development for DR
6.7.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
6.7.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
6.7.3 TriLipix (Abbott): No New Development for Promising Drug
6.7.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
6.7.5 Darapladib (GlaxoSmithKline): Possible New Use for Atherosclerosis Drug
6.7.6 Jetrea (ThromboGenics/Novartis): Possibilities in DME?
7. Regional Market Breakdown, 2014-2025
7.1 Which Markets Hold the Most Revenue Growth Potential?
7.2 The US: Leading Market for Retinal Diseases
7.3 Japan: Strong Market Potential
7.4 EU5: Ageing Populations to Drive Market Growth
7.5 BRIC Nations: The Biggest Growth Driver for the Market
8. Qualitative Industry and Market Analysis, 2015-2025
8.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
8.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
8.3 Opportunities: New Markets and R&D Synergies
8.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
8.5 Social: Low Diagnosis, Low Compliance
8.6 Technological: Innovation for the Eye
8.7 Economic: Off-Label Treatment and Reimbursement Issues
8.8 Political: The Demography and Diabetes Challenges
9. Research Interviews
9.1 Interview with Philip G. Ralston, Jr., MacuCLEAR (Part 1)
9.1.1 MC-1101: Identifying and Treating Chiou Syndrome
9.1.2 Preventing Dry AMD Progression
9.1.3 Treating the Root Cause of Dry AMD
9.1.4 Phase 3: Endpoints and Prospects for MC-1101
9.2 Interview with Philip G. Ralston, Jr., MacuCLEAR (Part 2)
9.2.1 MC-1101: Progress in Clinical Trials
9.2.2 MC-1101 More Effective in Early to Mid-Range AMD
9.2.3 Partnerships and Expected Launch of MC-1101
10. Report Conclusions
10.1 The Age of Lucentis: Nearing Its Conclusion?
10.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
10.3 Indications Outside Wet AMD to Gain in Importance
10.4 Dry AMD Market Has Huge Potential
10.5 Fovista Most Prominent Among the Pipeline Candidates
10.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics
【レポート販売概要】
■ タイトル:加齢黄斑変性(AMD)及びその他の網膜疾患治療薬の世界市場:滲出型(ウェット型)、萎縮型(ドライ型)、糖尿病性網膜症■ 英文:Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025
■ 発行日:2015年2月
■ 調査会社:visiongain
■ 商品コード:VGAIN503045
■ 調査対象地域:グローバル
- 世界のエピジェネティクス市場:Global Epigenetics Market 2014-2018TechNavio forecasts The Global Epigenetics Market 2014-2018 with a CAGR of 28.79 percent for the period 2013-2018. Several driving factors and trends will contribute to this growth-all of which will be outlined with detail in this report. TechNavio’s analysts use a unique methodology to scrutinize individual vendor performance, trends, drivers and challenges, and a number of other factors to provi …
- Pakistan State Oil Company Limited:石油・ガスバリューチェーン分析レポート2013Pakistan State Oil Company Limited Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Pakistan State Oil Company Limited" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Pakistan State Oil Company Limited”. The report provides key information relating to oil and gas assets of the company along with its operatio …
- 世界のベンチレーター(人工呼吸器)市場:医療機器パイプライン分析2016Ventilators - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Ventilators - Medical Devices Pipeline Assessment, 2016" provides an overview of Ventilators currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews maj …
- 電気生理学(EP)研究室デバイス(医療機器)のグローバル市場(2012-2018)Global Electrophysiology (EP) Laboratory Devices sector is projected to reach US$636 million by 2016. The North America accounts for nearly 34% (2015) of the global share while Europe claims approximately 30% (2018). Asia-Pacific is the fastest growing region with a CAGR of 9.2% driving a market value of US$150 million by 2015. On a global scale, projections for X-Ray Systems indicate more than 30 …
- 世界のメシチレン市場2015The Global Mesitylene Industry Report 2015 is a professional and in-depth study on the current state of the Mesitylene industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Mesitylene market analysis is provided for the international markets including development trends, competitive landscape analysis, …
- グローバルM2Mセキュリティー及びプライバシー市場:課題と機会Machine-to-Machine (M2M) applications will be developed in various sectors of the industry at a rapid pace over the next five years, reaching an inflexion point by 2020 as the Internet of Things (IoT) begins a high growth phase. With increasingly more devices connected to the Internet in which critical business processes depend, the threats to applications increase in terms of incidence, severity, …
- 北米の技術教育・職業教育市場2016-2020About the Technical and Vocational Education (TVE) Market in North America TVE equips people with essential skills to successfully transition from classrooms to workplaces. In many countries, it is referred to as technical vocational education and training (TVET). The TVE system in North America is complex as it incorporates various grade levels, providers, and subject areas. This complexity is be …
- 試験・検査・認証(TIC)サービスの世界市場:航空分野、医療・製薬分野The factors such as new regulations and standards, outsourcing of the testing, inspection, and certification services, concern about product quality and safety, and globalization of the trade are driving the testing, inspection, and certification market. Regulatory bodies are involved in developing and publishing the new standards to meet the international quality and also to satisfy the end-users …
- ロシアのエネルギー産業分析:Analyzing the Energy Industry in RussiaThe global energy industry has explored many options to meet the growing energy needs of industrialized economies wherein production demands are to be met with supply of power from varied energy resources worldwide. There has been a clearer realization of the finite nature of oil resources and the ever higher pushing demand for energy. The world has yet to stabilize on the complex geopolitical und …
- 塩素の世界市場:用途(EDC/PVC、C1/C2芳香族化合物、無機化合物、有機化合物、塩素化中間体、イソシアン酸、酸化プロピレン等)および地域別分析Chlorine is widely used in the EDC/PVC, inorganic chemicals, organic chemicals, C1/C2, aromatics, chlorinated intermediaries, isocyanates, propylene oxide, pulp & paper, water treatment, and various other industries global. In 2013, chlorine had a total demand of 64,072KT globally. The Asia-pacific region is the biggest market of chlorine, accounting for more than half of the total global demand. …
- 静脈瘤治療装置の世界市場:種類別(静脈内切除、硬化療法、外科的結紮・剥離)、地域別、セグメント予測The global varicose veins treatment devices market is expected to reach USD 1.7 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 6.3% during the forecast period. Rising investments by the key healthcare companies to develop innovative and effective products is likely to drive the growth. Varicose veins can be unsightly and can lead to …
- ザクロエキス(エクストラ)の世界市場2015Pomegranate, Ext. (CAS 84961-57-9) Market Research Report 2015 aims at providing comprehensive data on Pomegranate, Ext. market globally and regionally (Europe, Asia, North America, Latin America etc.) The report includes Pomegranate, Ext. description, covers its application areas, manufacturing methods, patterns. It captures Pomegranate, Ext. market trends, pays close attention to Pomegranate, Ex …
- LED用蛍光体市場2014※当レポートはLED用蛍光体の市場機会、新規蛍光体材料、関連メーカーの商品・マーケット戦略、今後の市場予測などをまとめました。 This new NanoMarkets report provides a thorough analysis of the latest opportunities in the LED phosphor markets. It builds on NanoMarkets’ successful 2012 phosphor report and shows how the phosphor market is shifting in response to latest developments in both display backlighting and general illumination markets. In this years’ repor …
- 航空機用燃料タンクの世界市場予測(~2025年)Increasing aircraft demand is expected to drive the aircraft fuel tanks market growth.The aircraft fuel tanks market is projected to grow from USD 869 million in 2019 to USD 954 million by 2025, at a CAGR of 1.6% during the forecast period. Safety of fuel tanks is of prime importance in order to prevent fatal accidents due to leaks and the flammable nature of the fuel. Proper inserting is necessar …
- フライボード 用品の世界市場2017-2021About Flyboarding Equipment The soft adventure sporting goods market, including flyboarding, holds great potential globally. It is mainly driven by the growing interest of consumers in outdoor recreational activities and the availability of a wide range of flyboarding equipment. In addition, the tourism industry has also encapsulated water sports among the various activities available for domestic …